Interleukin 6: A biomarker for COVID-19 progression

Area of Science:

• Immunology
• Virology
• Critical Care Medicine

Background:

• COVID-19, caused by SARS-CoV-2, rapidly became a global pandemic.
• Severe COVID-19 is associated with a hyperactive immune response, leading to cytokine release syndrome (CRS).
• Elevated levels of interleukin-6 (IL-6) are observed in severe COVID-19 cases, correlating with multi-organ dysfunction and respiratory failure.

Purpose of the Study:

• To investigate the role of interleukin-6 (IL-6) as a biomarker for COVID-19 progression.
• To highlight IL-6's significance in predicting disease severity and patient outcomes.

Main Methods:

• Review of existing clinical data and studies on COVID-19 patients.
• Analysis of serum IL-6 levels in relation to disease severity and complications.
• Evaluation of therapeutic strategies targeting IL-6.

Main Results:

• Serum IL-6 levels are significantly elevated in patients with severe COVID-19.
• High IL-6 concentrations are linked to increased morbidity and mortality.
• Targeting IL-6, for example, with anti-interleukin-6 receptor monoclonal antibodies, shows potential in reducing COVID-19 severity.

Conclusions:

• Interleukin-6 serves as a reliable biomarker for predicting COVID-19 progression and patient outcomes.
• Monitoring IL-6 levels is crucial for assessing disease severity.
• Inhibition of IL-6 activity represents a promising therapeutic target for managing severe COVID-19.